Lymphoma Clinical Trials

Showing 1381-1400 of 1,633 trials

A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment

NCT01561911

The Purpose of this study is to evaluate the safety and tolerability, and the biological effects of the chimeric anti-CD40 monoclonal antibody Chi Lob 7/4, given intravenously, weekly for 4 weeks in the treatment of patients with advanced malignancies refractory to conventional anti-cancer treatment.

CancerNeoplasmsLymphoma+2 more

Cancer Research UK29 participantsStarted Jul 2007

Edgbaston, Birmingham, United Kingdom • Tremona Road,, Southampton, United Kingdom

UNKNOWNPhase 1/2

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

NCT02134262

The purpose of this study is to evaluate the safety, efficacy and blood kinetics of autologous T cells genetically modified to express anti-CD19 Chimeric Antigen Receptor in patients with relapsed or refractory B-Cell Non-Hodgkin Lymphoma.

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Jichi Medical University18 participantsStarted May 2014

Shimotsuke, Tochigi, Japan

A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Related Searches

Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma

Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma

CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer

Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma

Metabolic Syndrome in Childhood Cancer Survivors

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma

CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas

Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

AZD6738 First Time in Patient Multiple Ascending Dose Study

Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT